European clinical trial finds XVIVO's heart technology reduces post-transplant complications by 44% compared to ice-based preservation.
European clinical trial shows XVIVO's heart technology reduces severe complications post-transplantation, with a 44% lower risk compared to ice-based preservation. The study, published in The Lancet, compared 204 patients across 15 trial sites in eight European countries. XVIVO's Heart Assist Transport device with hypothermic oxygenated perfusion (HOPE) offers safer and more effective donor heart preservation in clinical heart transplantation.
August 16, 2024
4 Articles